8-K ·Filed Apr 13, 2026
8-K context-dependent: Items 7.01
Actionable Insight • Neutral
Monitor for actual clinical data from the upcoming Phase 2b trial, as the webcast provided only forward-looking statements without new results.
Final — all horizons settled through T+60d
EVMN ▼ -49.27% at T+60d
NEUTRAL call -49.27% · α vs SPY -57.79% · entry $26.63 → $13.51
T+1d
+1.16%
call +1.16% · α +0.39%
$26.94
settled 7mo ago
T+5d
+5.41%
call +5.41% · α +4.01%
$28.07
settled 6mo ago
T+20d
-12.84%
call -12.84% · α -19.14%
$23.21
settled 6mo ago
T+60d
-49.27%
call -49.27% · α -57.79%
$13.51
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
Evommune hosted a webcast on April 13, 2026, highlighting its EVO756 program targeting MRGPRX2 for migraine treatment, including plans for a Phase 2b trial in mid-2026. The filing is a standard Regulation FD disclosure of a public presentation.
Key Facts
- Hosted a webcast on migraine treatment landscape and EVO756's role
- Presentation included forward-looking statements about EVO756's potential and trial timeline
- No new financial data or material updates disclosed
- Filing is routine Regulation FD disclosure of a public event
Financial Impact
No immediate financial impact
Risk Factors
- Forward-looking statements may not materialize
- Clinical trial timelines are subject to change
Market Snapshot
Exchange
NYSE
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-152864 |
| Document: evmn-ex99_1.htm | 0001193125-26-152864 |
| Document: 0001193125-26-152864-index-headers.html | 0001193125-26-152864 |
| Document: 0001193125-26-152864-index.html | 0001193125-26-152864 |
| Document: 0001193125-26-152864.txt | 0001193125-26-152864 |
15 reports for EVMN
75% Hit rate @ T+60 Went positive at some point 3 of 5 best @ T+60▲ +41.15%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $7.21 | awaiting T+60 | — | $5.16 (−28.43%) |
Sep 15, 2026 6w ago | 8-K | $9.99 | awaiting T+60 | — | $5.16 (−48.35%) |
Jul 30, 2026 12w ago | 8-K | $11.35 $5.10 | ▼ −55.07% | ▼ −57.53% | $5.16 (−54.54%) |
Jul 10, 2026 15w ago | Insider Cluster | $12.10 $6.61 | ▼ −45.37% | ▼ −49.37% | $5.16 (−57.36%) |
Jun 29, 2026 17w ago | 8-K | $15.05 $9.60 | ▲ +36.21% | ▲ +40.60% | $5.16 (+65.71%) |
Jun 24, 2026 17w ago | Insider Cluster | $24.13 $9.65 | ▼ −60.01% | ▼ −63.74% | $5.16 (−78.62%) |
Jun 3, 2026 20w ago | Insider Cluster | $20.69 $13.23 | ▲ +36.06% | ▲ +37.94% | $5.16 (+75.06%) |
Jun 2, 2026 21w ago | 144 | $19.73 $13.48 | ▼ −31.68% | ▼ −34.18% | $5.16 (−73.85%) |
Jun 1, 2026 21w ago | Insider Cluster | $19.82 $14.11 | ▼ −28.81% | ▼ −29.93% | $5.16 (−73.97%) |
May 28, 2026 21w ago | 144 | $23.23 $13.67 | ▲ +41.15% | ▲ +42.34% | $5.16 (+77.79%) |
Showing 10 of 15
US Market Status
Market Closed — Opens Thu (11h 43m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers